Jury out on ivermectin for COVID-19 prevention and treatment: Cochrane
The review finds no support for the drug's use in infected patients, but the evidence base is limited, acknowledges German team
The efficacy and safety of the antiparasitic ivermectin for prevention or treatment of COVID-19 remains uncertain, according to a new Cochrane review.
While laboratory tests have shown that ivermectin can slow the reproduction of SARS-CoV-2, the review found no evidence to support its use in infected patients.
The research team, from the University Hospital of Wurzburg in Germany, reviewed 14 randomised controlled trials with a total of 1678 patients.
Treatment of mild to moderate COVID-19 was investigated in 13 studies comparing ivermectin with placebo or with no treatment in addition to usual care.
